- In patients with mantle cell lymphoma (MCL) ineligible/unwilling to undergo high-dose chemotherapy autologous stem cell transplant (ASCT), radioimmunotherapy (RIT) with 90Y ibritumomab tiuxetan (90Y) markedly improved survival outcomes.
Why this matters
- Prognosis is poor in MCL, with survival rarely exceeding 5 years.
- 8-year follow-up of a phase 2 study to investigate consolidation 90Y in 46 patients with MCL chemosensitive to first-line (1L) or second-line (2L) therapy who were high-dose chemotherapy ASCT ineligible/unwilling.
- 34 patients received 90Y consolidation after 1L therapy; 12 after 2L therapy.
- Median patient age, 60 (range, 30-78) years.
- Funding: Schering AG.
- In patients with 1L induction, 90Y consolidation increased complete response (CR) rate from 41% to 91%.
- In patients with 2L induction, 90Y consolidation increased CR from 16% to 75%.
- Survival outcomes with 1L vs 2L induction, respectively:
- Median PFS: 3.3 years vs 1.8 years (P<.05>
- Median OS: 6.5 years vs 2.2 years (P<.05>
- Limited sample size.